Fennec Pharmaceuticals (FENC) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

$0.02

Surprise

—

Score today

6.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 — benzinga, 2026-08-12
• Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 — benzinga, 2026-08-12
• Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate — benzinga, 2026-08-11

TrendMatrix currently rates FENC Hold at 6.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.25

Price target

$15.37

Stop

$10.50

Upside to target

+36.6%

Reward-to-risk

2.4:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$395.9M

P/E (fwd)

11.9

52-week range

$5.65–$13.25

Off 52-week high

15.1%

RSI (14)

63

Volume vs avg

1.10×

Score today

6.5/10